These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 30042266)

  • 1. [Endocrine Organ Dysfunction with Immune-Checkpoint Inhibitors].
    Inaba H; Ariyasu H; Kurimoto C; Iwakura H; Akamizu T
    Gan To Kagaku Ryoho; 2018 Jul; 45(7):1031-1035. PubMed ID: 30042266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
    Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyrotoxicosis and Adrenocortical Hormone Deficiency During Immune-checkpoint Inhibitor Treatment for Malignant Melanoma.
    Ariyasu H; Inaba H; Ota T; Yamaoka H; Furukawa Y; Iwakura H; Doi N; Yamamoto Y; Akamizu T
    In Vivo; 2018; 32(2):345-351. PubMed ID: 29475919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management.
    Sznol M; Postow MA; Davies MJ; Pavlick AC; Plimack ER; Shaheen M; Veloski C; Robert C
    Cancer Treat Rev; 2017 Jul; 58():70-76. PubMed ID: 28689073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy.
    King GT; Sharma P; Davis SL; Jimeno A
    Drugs Today (Barc); 2018 Feb; 54(2):103-122. PubMed ID: 29637937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.
    Yao L; Jia G; Lu L; Bao Y; Ma W
    Int Immunopharmacol; 2020 Aug; 85():106628. PubMed ID: 32474388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Management of Toxicities of Immune Checkpoint Inhibitors].
    Horio Y
    Gan To Kagaku Ryoho; 2017 Mar; 44(3):185-190. PubMed ID: 28292987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know).
    Ruggeri RM; Campennì A; Giuffrida G; Trimboli P; Giovanella L; Trimarchi F; Cannavò S
    J Endocrinol Invest; 2019 Jul; 42(7):745-756. PubMed ID: 30471004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of immune related adverse events induced by immune checkpoint inhibition.
    Teufel A; Zhan T; Härtel N; Bornschein J; Ebert MP; Schulte N
    Cancer Lett; 2019 Aug; 456():80-87. PubMed ID: 31051213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.
    Le Burel S; Champiat S; Mateus C; Marabelle A; Michot JM; Robert C; Belkhir R; Soria JC; Laghouati S; Voisin AL; Fain O; Mékinian A; Coutte L; Szwebel TA; Dunogeant L; Lioger B; Luxembourger C; Mariette X; Lambotte O
    Eur J Cancer; 2017 Sep; 82():34-44. PubMed ID: 28646772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmune complications of immunotherapy: pathophysiology and management.
    Chan KK; Bass AR
    BMJ; 2020 Apr; 369():m736. PubMed ID: 32253223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine side effects induced by immune checkpoint inhibitors.
    Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
    Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
    Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-related adverse events in various organs caused by immune checkpoint inhibitors.
    Okiyama N; Tanaka R
    Allergol Int; 2022 Apr; 71(2):169-178. PubMed ID: 35101349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies.
    Byun DJ; Wolchok JD; Rosenberg LM; Girotra M
    Nat Rev Endocrinol; 2017 Apr; 13(4):195-207. PubMed ID: 28106152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
    Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
    Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine toxicities of immune checkpoint inhibitors.
    Wright JJ; Powers AC; Johnson DB
    Nat Rev Endocrinol; 2021 Jul; 17(7):389-399. PubMed ID: 33875857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of endocrine-related immune-related adverse events in Japanese subjects with various types of cancer.
    Iwamoto Y; Kimura T; Iwamoto H; Sanada J; Fushimi Y; Katakura Y; Tatsumi F; Shimoda M; Nakanishi S; Mune T; Kaku K; Kaneto H
    Front Endocrinol (Lausanne); 2023; 14():1079074. PubMed ID: 36755909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common endocrine system adverse events associated with immune checkpoint inhibitors.
    Li Y; Zhao J; Wang Y; Xu Y; Li R; Zhao Y; Dong X; Yao X; Li Y
    Cancer Pathog Ther; 2024 Jul; 2(3):164-172. PubMed ID: 39027145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.